Spain registered a total of 59 new cases of monkeypox on Wednesday and is set to take action, including ordering vaccines and antivirals through a European Union acquisition.
A total of 59 cases were detected by the PCR test, 20 of which were confirmed by genomic sequencing, Spanish Health Minister Carolina Darias told a news conference, according to AFP, quoted by Agerpres.
“It is reasonable to assume that all these people are positively diagnosed with the disease,” said Cristobal Belda, director of the Carlos III Research Institute. A total of 171 suspicious cases were detected in the country.
Spain plans to buy Imvanex and Tecovirimat antivirals through a group EU purchase to curb the spread of the virus, Darias said.
The European Organization for Health Emergency Response Authority (HERA) “will make the vaccine available to Member States, in this case the Imvanex vaccine,” she said, without specifying the quantities or timing of distribution.
“HERA will set deadlines and doses will be distributed fairly among Member States for these products with limited production and limited access,” she said.
Imvanex, from the Bavarian Nordic laboratory, is a 3rd generation vaccine authorized in Europe since 2013 and indicated against smallpox in adults.
There are no specific treatments or vaccines for smallpox in monkeys, but the multiplication of cases can be stopped by vaccination against smallpox, the WHO explained.
Smallpox has been detected in recent weeks in Europe and North America, a rare disease that originates in Africa and is usually treated spontaneously by humans.
Editor: Adrian Dumitru